Kostas Stamatopoulos, MD, PhD, Center for Research and Technology Hellas, Thessaloniki, Greece, gives an overview of some of the presentations that took place during a satellite symposium at ESH CLL 2022, which focused on how to improve and personalize the management of patients with chronic lymphocytic leukemia (CLL). First, Dr Stamatopoulos discusses some important factors to consider when making treatment decisions in CLL, including patient profile, drug profile, patient preference and biological background of the malignancy. Dr Stamatopoulos then highlights some of the presentations that were given, including Dr Richard Rosenquist’s talk on TP53 aberration, IgHV mutational status, and emerging biomarkers of disease. To conclude, Dr Stamatopoulos highlights some more discussions from this session, and the importance of further improving tools for measuring measurable residual disease (MRD) in CLL. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.